Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: f
View:
• Migraine with or without aura diagnosis according to ICHD-3 criteria
• \<8 migraine days per month
• Be able to read, write and understand instructions.
• Have internet access and mail address
• Signing of the informed consent
Locations
Other Locations
Spain
Hospital Universitari Vall d'Hebron
RECRUITING
Barcelona
Contact Information
Primary
Marta Torres-Ferrús, PhD
cefalea@vhir.org
(+34)934893000
Time Frame
Start Date: 2024-01-25
Estimated Completion Date: 2024-12
Participants
Target number of participants: 108
Treatments
episodic migraine
Patients with episodic migraine will be asked to treat four spontaneous migraine attacks with sumatriptan 50 milligrams. They will register the headache characteristics and whether or not the treatment was effective.
Sponsors
Leads: Hospital Universitari Vall d'Hebron Research Institute
Collaborators: Instituto de Salud Carlos III